Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERACYTE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERACYTE's regulatory disclosures and financial reporting.
VERACYTE, INC. Vice President and Chief Accounting Officer Jonathan Wygant reported an exercise-and-sell transaction in company stock. On May 22, 2026, he exercised stock options for 24,000 shares of common stock at $24.80 per share, then sold 24,000 shares of common stock in an open-market sale at a weighted average price of $45.401 per share, with individual sale prices ranging from $45.07 to $45.69. Following these transactions, he directly owns 45,434 shares of Veracyte common stock. The option exercised is reported as fully vested and, after exercise, no remaining shares from that option grant are outstanding.
VERACYTE, INC. director Robert S. Epstein reported an open-market sale of 10,000 shares of common stock on May 20, 2026 at a weighted average price of $44.01 per share, with individual sale prices ranging from $44.00 to $44.10.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following these sales, Epstein directly owns 52,446 shares of Veracyte common stock.
Veracyte, Inc. ownership disclosure: Artisan Partners entities report beneficial ownership of 5,496,370 shares of common stock, representing 6.9% of the class based on 79,458,427 shares outstanding as of 02/20/2026. The filing attributes 4,889,589 shares to shared voting power and 5,496,370 shares to shared dispositive power. The shares were acquired on behalf of discretionary clients of Artisan Partners Limited Partnership and are reported through a joint filing executed 05/13/2026.
State Street Corporation reported beneficial ownership of 5,043,590 shares of Veracyte Inc. common stock, representing 6.3% of the class as of 03/31/2026. The filing lists shared voting power of 4,800,493 shares and shared dispositive power of 5,043,590 shares. The filing identifies several State Street advisory subsidiaries as holders of the position.
VERACYTE, INC. senior vice president and general counsel Annie McGuire reported selling a total of 10,204 shares of common stock in open-market transactions on May 6, 2026. The shares were sold in two blocks at $40.00 and $38.05 per share.
After these sales, she directly owns 143,708 shares of Veracyte common stock. According to a footnote, the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2025, indicating they were scheduled in advance.
Ann McGuire reported a proposed/actual sale of common stock under a 10b5-1 plan. The filing shows a 10b5-1 sale of 6,658 shares on 03/04/2026 that generated $236,725.09. The notice references Performance Stock Units dated 02/28/2026 and lists Morgan Stanley Smith Barney LLC as the broker.
Veracyte Inc. amendment to Schedule 13G/A reports that FMR LLC (and Abigail P. Johnson through related entities) beneficially owns 7,703,848.74 shares of common stock, representing 9.7% of the class. The filing lists sole dispositive power of 7,703,848.74 shares and discloses a related Exhibit 99 13d-1(k)(1) agreement.